Episurf Medical AB (publ) (EPIS-B.ST)
SEK 0.12
(-0.82%)
SEK 0.12
(-0.82%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -94.8 Million SEK | -22.64% |
| 2022 | -77.3 Million SEK | -11.22% |
| 2021 | -69.5 Million SEK | -7.59% |
| 2020 | -64.6 Million SEK | 8.5% |
| 2019 | -70.6 Million SEK | -22.15% |
| 2018 | -57.8 Million SEK | 5.39% |
| 2017 | -61.09 Million SEK | 0.93% |
| 2016 | -61.66 Million SEK | -40.23% |
| 2015 | -43.97 Million SEK | -33.6% |
| 2014 | -32.91 Million SEK | -44.0% |
| 2013 | -22.85 Million SEK | -44.94% |
| 2012 | -15.76 Million SEK | -253.69% |
| 2011 | -4.45 Million SEK | -60.02% |
| 2010 | -2.78 Million SEK | -415.74% |
| 2009 | -540.24 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -21.4 Million SEK | -4.39% |
| 2024 Q3 | -15.9 Million SEK | 25.7% |
| 2024 Q1 | -20.5 Million SEK | 6.39% |
| 2023 Q3 | -20.8 Million SEK | 28.03% |
| 2023 FY | -94.8 Million SEK | -22.64% |
| 2023 Q2 | -28.9 Million SEK | -25.65% |
| 2023 Q4 | -21.9 Million SEK | -5.29% |
| 2023 Q1 | -23 Million SEK | 2.95% |
| 2022 Q2 | -19.4 Million SEK | -17.58% |
| 2022 FY | -77.3 Million SEK | -11.22% |
| 2022 Q1 | -16.5 Million SEK | 12.7% |
| 2022 Q4 | -23.7 Million SEK | -30.94% |
| 2022 Q3 | -18.1 Million SEK | 6.7% |
| 2021 Q3 | -15.9 Million SEK | 10.17% |
| 2021 FY | -69.5 Million SEK | -7.59% |
| 2021 Q2 | -17.7 Million SEK | -5.99% |
| 2021 Q4 | -18.9 Million SEK | -18.87% |
| 2021 Q1 | -16.7 Million SEK | -3.09% |
| 2020 FY | -64.6 Million SEK | 8.5% |
| 2020 Q3 | -15.4 Million SEK | -6.94% |
| 2020 Q4 | -16.2 Million SEK | -5.19% |
| 2020 Q2 | -14.4 Million SEK | 19.55% |
| 2020 Q1 | -17.9 Million SEK | 4.28% |
| 2019 FY | -70.6 Million SEK | -22.15% |
| 2019 Q1 | -14.6 Million SEK | 4.58% |
| 2019 Q2 | -18.9 Million SEK | -29.45% |
| 2019 Q3 | -17.5 Million SEK | 7.41% |
| 2019 Q4 | -18.7 Million SEK | -6.86% |
| 2018 Q4 | -15.3 Million SEK | -18.6% |
| 2018 FY | -57.8 Million SEK | 5.39% |
| 2018 Q2 | -16.3 Million SEK | -22.56% |
| 2018 Q3 | -12.9 Million SEK | 20.86% |
| 2018 Q1 | -13.3 Million SEK | 13.94% |
| 2017 Q3 | -13.61 Million SEK | -4.78% |
| 2017 Q2 | -12.99 Million SEK | 31.76% |
| 2017 Q4 | -15.45 Million SEK | -13.54% |
| 2017 Q1 | -19.03 Million SEK | -3.16% |
| 2017 FY | -61.09 Million SEK | 0.93% |
| 2016 Q4 | -18.45 Million SEK | -22.68% |
| 2016 Q3 | -15.04 Million SEK | 8.69% |
| 2016 Q1 | -11.69 Million SEK | 17.33% |
| 2016 Q2 | -16.47 Million SEK | -40.84% |
| 2016 FY | -61.66 Million SEK | -40.23% |
| 2015 Q3 | -10.9 Million SEK | 4.18% |
| 2015 Q1 | -7.53 Million SEK | 6.48% |
| 2015 Q4 | -14.14 Million SEK | -29.7% |
| 2015 FY | -43.97 Million SEK | -33.6% |
| 2015 Q2 | -11.38 Million SEK | -51.12% |
| 2014 Q3 | -7.3 Million SEK | 21.66% |
| 2014 FY | -32.91 Million SEK | -44.0% |
| 2014 Q2 | -9.32 Million SEK | -13.16% |
| 2014 Q1 | -8.23 Million SEK | -34.04% |
| 2014 Q4 | -8.05 Million SEK | -10.31% |
| 2013 Q1 | -5.32 Million SEK | 9.93% |
| 2013 Q2 | -6.6 Million SEK | -24.03% |
| 2013 FY | -22.85 Million SEK | -44.94% |
| 2013 Q4 | -6.14 Million SEK | -28.71% |
| 2013 Q3 | -4.77 Million SEK | 27.77% |
| 2012 Q1 | -3.7 Million SEK | -150.28% |
| 2012 Q2 | -3.41 Million SEK | 7.73% |
| 2012 Q3 | -2.73 Million SEK | 19.94% |
| 2012 Q4 | -5.91 Million SEK | -116.34% |
| 2012 FY | -15.76 Million SEK | -253.69% |
| 2011 Q4 | -1.47 Million SEK | -19.34% |
| 2011 FY | -4.45 Million SEK | -60.02% |
| 2011 Q2 | -2.09 Million SEK | -192.78% |
| 2011 Q1 | -714.87 Thousand SEK | 11.77% |
| 2011 Q3 | -1.23 Million SEK | 40.78% |
| 2010 FY | -2.78 Million SEK | -415.74% |
| 2010 Q2 | -556.5 Thousand SEK | -26.48% |
| 2010 Q4 | -810.27 Thousand SEK | 17.28% |
| 2010 Q1 | -439.98 Thousand SEK | 0.0% |
| 2010 Q3 | -979.48 Thousand SEK | -76.01% |
| 2009 FY | -540.24 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.83 Million SEK | -21.79% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 191.594% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 191.594% |
| Arcoma AB | 2.56 Million SEK | 3797.348% |
| Bactiguard Holding AB (publ) | -138.38 Million SEK | 31.494% |
| BICO Group AB (publ) | -835.7 Million SEK | 88.656% |
| Boule Diagnostics AB (publ) | 24.97 Million SEK | 479.549% |
| CellaVision AB (publ) | 130.3 Million SEK | 172.75% |
| Clinical Laserthermia Systems AB (publ) | -79.79 Million SEK | -18.809% |
| Chordate Medical Holding AB (publ) | -29.18 Million SEK | -224.806% |
| C-Rad AB (publ) | 35.52 Million SEK | 366.824% |
| Duearity AB (publ) | -26.19 Million SEK | -261.97% |
| Dignitana AB (publ) | -17.36 Million SEK | -445.989% |
| Getinge AB (publ) | 2.41 Billion SEK | 103.93% |
| Scandinavian Real Heart AB (Publ) | -67.97 Million SEK | -39.458% |
| Iconovo AB (publ) | -45.89 Million SEK | -106.564% |
| Integrum AB (publ) | 4.03 Million SEK | 2450.912% |
| Luxbright AB (publ) | -25.37 Million SEK | -273.594% |
| Mentice AB (publ) | -2.81 Million SEK | -3265.282% |
| OssDsign AB (publ) | -130.49 Million SEK | 27.352% |
| Paxman AB (publ) | 8.33 Million SEK | 1238.055% |
| Promimic AB (publ) | -9.22 Million SEK | -927.977% |
| Qlife Holding AB (publ) | -159.95 Million SEK | 40.734% |
| SciBase Holding AB (publ) | -55.58 Million SEK | -70.55% |
| ScandiDos AB (publ) | -14.64 Million SEK | -547.232% |
| Sectra AB (publ) | 428.38 Million SEK | 122.129% |
| Sedana Medical AB (publ) | -59.61 Million SEK | -59.028% |
| Senzime AB (publ) | -134.14 Million SEK | 29.332% |
| SpectraCure AB (publ) | -20.44 Million SEK | -363.774% |
| Stille AB | 26.64 Million SEK | 455.776% |
| Vitrolife AB (publ) | -3.85 Billion SEK | 97.538% |
| Xvivo Perfusion AB (publ) | 91.82 Million SEK | 203.245% |